At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
RVMD Revolution Medicines, Inc.
Post-Mkt 09-17 19:03:04 EDT
196.94
+1.02
+0.52%
盘后197.00
+0.06+0.03%
19:02 EDT
High202.02Low194.80Vol1.82M
Open198.53D1 Closing195.92Amplitude3.69%
Mkt Cap42.21BTradable Cap36.43BTotal Shares214.34M
T/O360.65MT/O Rate0.98%Tradable Shares185.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Movement Alert｜Revolution Medicines, Inc. Falls 5.1% in Regular Trading, Trading at $194.58
Market Focus  ·  09-17 03:20
Movement Alert｜Revolution Medicines, Inc. Falls 5.1% in Regular Trading, Trading at $194.58
Revolution Medicines gets orphan designation for pancreatic cancer treatment
TIPRANKS  ·  09-16 03:00
Revolution Medicines gets orphan designation for pancreatic cancer treatment
Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), ArriVent BioPharma, Inc. (AVBP)
TIPRANKS  ·  09-15
Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), ArriVent BioPharma, Inc. (AVBP)
Revolution Medicines Gets US FDA Breakthrough Therapy Designation for Rasonque To Treat Pancreatic Cancer
MT Newswires Live  ·  09-15
Revolution Medicines Gets US FDA Breakthrough Therapy Designation for Rasonque To Treat Pancreatic Cancer
Revolution Medicines granted Breakthrough Therapy Designation to Rasonque by FDA
TIPRANKS  ·  09-15
Revolution Medicines granted Breakthrough Therapy Designation to Rasonque by FDA
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for Rasonque™ (Daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
THOMSON REUTERS  ·  09-15
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for Rasonque™ (Daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Cooper Co (COO)
TIPRANKS  ·  09-14
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Cooper Co (COO)
Revolution Medicines Director Lorence H. Kim Disposes of 17,090 Common Shares Worth USD 3.57 Million
Reuters  ·  09-11
Revolution Medicines Director Lorence H. Kim Disposes of 17,090 Common Shares Worth USD 3.57 Million
Revolution Medicines Got a 'Miracle' Cancer Drug Approval. Wall Street Wants More.
Dow Jones  ·  09-11
Revolution Medicines Got a 'Miracle' Cancer Drug Approval. Wall Street Wants More.
Revolution Medicines to Gain From Drug Expansion, New Combination Therapies, Morgan Stanley Says
MT Newswires Live  ·  09-10
Revolution Medicines to Gain From Drug Expansion, New Combination Therapies, Morgan Stanley Says
Morgan Stanley Initiates Coverage on Revolution Medicines With Overweight Rating
MT Newswires Live  ·  09-10
Morgan Stanley Initiates Coverage on Revolution Medicines With Overweight Rating
Revolution Medicines, Inc. : Morgan Stanley Initiates Coverage with Overweight Rating; Price Target $255
THOMSON REUTERS  ·  09-10
Revolution Medicines, Inc. : Morgan Stanley Initiates Coverage with Overweight Rating; Price Target $255
BeOne Medicines FY26 H1 Net Income Climbs to Us$464.36 Million; Revenue Rises 32.3% to Us$3.22 Billion
Reuters  ·  09-10
BeOne Medicines FY26 H1 Net Income Climbs to Us$464.36 Million; Revenue Rises 32.3% to Us$3.22 Billion
Revolution Medicines Price Target Raised to $230.00/Share from $215.00 by Stifel
Dow Jones  ·  09-09
Revolution Medicines Price Target Raised to $230.00/Share from $215.00 by Stifel
Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)
TIPRANKS  ·  09-09
Analysts Offer Insights on Healthcare Companies: Collegium Pharmaceutical (COLL), Revolution Medicines (RVMD) and Intellia Therapeutics (NTLA)
Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Teva Pharmaceutical (TEVA)
TIPRANKS  ·  09-03
Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Teva Pharmaceutical (TEVA)
Buy Rating Reiterated on Daraxonrasib Strength, RASolve 301 Upsizing, and Unchanged $315 Price Target
TIPRANKS  ·  09-03
Buy Rating Reiterated on Daraxonrasib Strength, RASolve 301 Upsizing, and Unchanged $315 Price Target
NEJM publishes Phase 1/2 clinical data on daraxonrasib
TIPRANKS  ·  09-03
NEJM publishes Phase 1/2 clinical data on daraxonrasib
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
GlobeNewswire  ·  09-03
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
Revolution Medicines Director Lorence H. Kim Disposes of Common Shares Worth $11.21 Million
Reuters  ·  09-03
Revolution Medicines Director Lorence H. Kim Disposes of Common Shares Worth $11.21 Million

Introduction

Company Name.
Revolution Medicines, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Revolution Medicines, Inc., a clinical-stage oncology company, developing novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) Inhibitors designed to suppress oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company's RAS(ON) Inhibitors RMC-6236 (RASMULTI), RMC-6291 (RASG12C), and RMC-9805 (RASG12D) are in clinical development. Its additional RAS(ON) Inhibitors in its pipeline include RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), which are in IND-enabling development, and additional compounds targeting other RAS variants. The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Issue price:
--